O=Mega23 – putting Australian optometry on the world stage

Coming together for the first time, O=Mega23, the largest clinical conference and trade show for optometry in the Southern Hemisphere, and the fourth World...

SOVS' mobile optometry clinic hits the road

Twelve years in the making, Vision Bus Aotearoa was officially launched on 10 June at a University of Auckland ceremony attended by Governor-General Dame...

Boost for non-invasive method to assess ICP

A research project proposing a novel non-invasive method to measure intracranial pressure (ICP), in a safe and timely manner, has been awarded one of 17...

Live education is back on track!

With restrictions lifted for live meets again, the eye health event calendar is filling up fast. Pick your favourite educational events or try something...

DIY anti-VEGF

Ashvattha Therapeutics’ phase 1 trial of patient-administered subcutaneous doses of its anti-VEGF therapy have shown it to be safe and well tolerated in...

Budget 2022

Titled ‘A Secure Future’, the 2022 Budget included $191m over two years for Pharmac and $168m for the Māori Health Authority, as part of a record-breaking...

RPE a haven for Ebola

Australian researchers have found retinal pigment epithelial (RPE) cells appear to be particularly susceptible to harbouring Ebola and other viruses.  Uveitis...

New macular dystrophy discovered

Researchers from the National Eye Institute (NEI) have identified a novel genetic macular dystrophy, which is yet to be named.  “Affected individuals had...

Tepezza – hyperglycaemia vigilance

Clinical trial results for Tepezza, the only thyroid eye disease (TED) treatment approved by the US Food and Drug Administration (FDA), have associated...

Oculoplastic labs, neoplasms and rosacea research

Pilot evaluation for an image-based eyelid lesion management service

SPONSORED: Freeform lens design into finished single vision lenses

ZEISS ClearView Finished Single Vision lenses represent a milestone in optics and aesthetics of stock lenses

Alcon augments drop portfolio

Alcon has signed a US$60 million agreement to acquire Kala Pharmaceuticals’ loteprednol etabonate products Eysuvis 0.25% for dry-eye disease (DED) and...

1722 articles found

Bottom Banner Advert